Targeting proteasomes as therapy in multiple myeloma

Advances in Experimental Medicine and Biology

Volumn 615, Issue , 2008, Pages 251-260

  Chauhan, Dharminder ^a   Hideshima, Teru ^a   Anderson, Kenneth C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Drug resistance; Myeloma; Proteasomes

Indexed keywords

2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMIDAZOLE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LENALIDOMIDE; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MITOXANTRONE; PROTEASOME; SALINOSPORAMIDE A; TANESPIMYCIN; TUBACIN; UBIQUITIN; UNCLASSIFIED DRUG; PROTEINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; APOPTOSIS; CANCER RESISTANCE; CELL CYCLE PROGRESSION; CLINICAL TRIAL; COLORECTAL CANCER; DNA MICROARRAY; DRUG DOSE ESCALATION; DRUG POTENTIATION; DRUG TARGETING; HUMAN; LYMPHOMA CELL; MULTIPLE MYELOMA; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; REVIEW; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM;

ANIMALS; APOPTOSIS; HUMANS; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 43249127114     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4020-6554-5_12     Document Type: Review

References (30)

1. Adams, J. (2002). Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 6, 493-500.
2. Adams, J. (2004). The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4, 349-360.
3. Berkers, C. R., Verdoes, M., Lichtman, E., Fiebiger, E., Kessler, B. M., Anderson, K. C., Ploegh, H. L., Ovaa, H., and Galardy, P. J. (2005). Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2, 357-362.
4. Chauhan, D. and Anderson, K. C. (2003). Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications. Apoptosis 8, 337-343.
5. Chauhan, D., Li, G., Shringarpure, R., Podar, K., Ohtake, Y., Hideshima, T. and Anderson, K. C. (2003). Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 63, 6174-6177.
6. Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005a). A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8, 407-419.
7. Chauhan, D., Hideshima, T., and Anderson, K. C. (2005b). Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol 45, 465-476.
8. Crawford, L., Walker, B., Ovaa, H., Chauhan, D., Anderson, K., Morris, T., and Irvine, T. (2006). Comparative selectivity and specificity of the proteasome inhibitor BzLLLCOCHO, PS-341, and MG-132. Cancer Res 66, 6379-6386.
9. Cusack, J. C., Jr., Liu, R., Houston, M., Abendroth, K., Elliott, P. J., Adams, J., and Baldwin, A. S., Jr. (2001). Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61, 3535-3540.
10. Feling, R. H., Buchanan, G. O., Mincer, T. J., Kauffman, C. A., Jensen, P. R., and Fenical, W. (2003). Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 42, 355-357.
11. Fribley, A., Zeng, Q., and Wang, C. Y. (2004). Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24, 9695-9704.
12. Goldberg, A. L. and Rock, K. (2002). Not just research tools - proteasome inhibitors offer therapeutic promise. Nat Med 8, 338-340.
13. Groll, M., Huber, R., and Potts, B. C. (2006). Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of betalactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 128, 5136-5141.
14. Haefner, B. (2002). NF-kappa B: arresting a major culprit in cancer. Drug Discov Today 7, 653-663.
15. Hamilton, A. L., Eder, J. P., Pavlick, A. C., Clark, J. W., Liebes, L., Garcia-Carbonero, R., Chachoua, A., Ryan, D. P., Soma, V., Farrell, K., et al. (2005). Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 23, 6107-6116.
16. Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dong, L., Castro, A., Palombella, V., et al. (2002). NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 28, 28.
17. Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Podar, K., Munshi, N. C., Mitsiades, N., and Anderson, K. C. (2003). Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101, 1530-1534.
18. Hideshima, T., Bradner, J. E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S. L. and Anderson, K. C. (2005). Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102, 8567-8572.
19. Kisselev, A. F., Callard, A., and Goldberg, A. L. (2006). Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 281, 8582-8590.
20. Landowski, T. H., Megli, C. J., Nullmeyer, K. D., Lynch, R. M., and Dorr, R. T. (2005). Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/ bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 65, 3828-3836.
21. LeBlanc, R., Catley, L. P., Hideshima, T., Lentzsch, S., Mitsiades, C. S., Mitsiades, N., Neuberg, D., Goloubeva, O., Pien, C. S., Adams, J., et al. (2002). Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62, 4996-5000.
22. Macherla, V. R., Mitchell, S. S., Manam, R. R., Reed, K. A., Chao, T. H., Nicholson, B., Deyanat- Yazdi, G., Mai, B., Jensen, P. R., Fenical, W. F., et al. (2005). Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 48, 3684-3687.
23. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., et al. (2002). Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99, 14374-14379.
24. Mitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V., Tai, Y. T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., et al. (2003). The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101, 2377-2380.
25. Obeng, E. A. and Boise, L. H. (2005). Caspase-12 and caspase-4 are not required for caspasedependent endoplasmic reticulum stress-induced apoptosis. J Biol Chem 280, 29578-29587.
26. Oberdorf, J., Carlson, E. J., and Skach, W. R. (2001). Redundancy of mammalian proteasome beta subunit function during endoplasmic reticulum associated degradation. Biochemistry 40, 13397-13405.
27. Pickart, C. M. (2004). Back to the future with ubiquitin. Cell 116, 181-190.
28. Richardson, P. G. (2004). A review of the proteasome inhibitor bortezomib in multiple myeloma. Expert Opin Pharmacother 5, 1321-1331.
29. Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J. L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005). Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352, 2487-2498.
30. Voorhees, P. M. and Orlowski, R. Z. (2006). The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 46, 189-213.